Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 132, Issue 1, Pages 3-12Publisher
WILEY
DOI: 10.1111/j.1365-2141.2005.05789.x
Keywords
alemtuzumab; infection risk; prophylaxis; lymphoproliferative disorders; screening
Categories
Ask authors/readers for more resources
There is an increasing use of monoclonal antibodies in the treatment of haematological malignancies. Alemtuzumab (Campath-H-1; Ilex Pharmaceuticals, San Antonio, TX, USA) is a monoclonal antibody reactive with the CD52 antigen used as first and second line therapy for two types of lymphoproliferative disorders: chronic lymphocytic leukaemia (CLL), and T-cell lymphomas [both peripheral (PTCL) and cutaneous (CTCL)]. With alemtuzumab therapy, viral, bacterial and fungal infectious complications are frequent, and may be life threatening. An understanding of the patients at highest risk and duration of risk are important in developing recommendations for empirical management, antimicrobial prophylaxis and targeted surveillance. This review discusses the infection risks associated with these lymphoproliferative disorders and their treatment, and provide detailed recommendations for screening and prophylaxis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available